Castrate-resistant Prostate Cancer Market Size, Trends, Growth, Key player and Future Outlook
Castrate-resistant Prostate Cancer Market Growth, Size, Trends Analysis - By Therapy - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Feb-2025 | Report ID: HLCA2541 | Pages: 1 - 239 | Formats*: |
| Category : Healthcare | |||
Castrate-resistant Prostate Cancer Market Introduction and Overview
According to SPER Market Research, the Global Castrate-resistant Prostate Cancer Market is estimated to reach USD 30.78 billion by 2034 with a CAGR of 8.91%.
The report includes an in-depth analysis of the Global Castrate-resistant Prostate Cancer Market, including market size and trends, product mix, Applications, and supplier analysis. The global castrate-resistant prostate cancer market was estimated at USD 13.11 billion in 2024 and is expected to increase at a CAGR of 8.91% between 2025 and 2034. This expansion is being driven by the rising prevalence of prostate cancer, particularly among the elderly, which is contributing to an increase in castrate-resistant prostate cancer (CRPC). Furthermore, advances in therapeutic alternatives, such as next-generation hormonal therapies, chemotherapy, and immunotherapies, are boosting market growth. The growing awareness of prostate cancer, as well as the need of early detection and treatment, are further driving market expansion.
By Therapy Insights: The hormonal therapy segment led the global castrate-resistant prostate cancer market in 2024, capturing a large revenue share due to the success of advanced hormonal therapies in treating CRPC. Hormonal therapies like enzalutamide and abiraterone target the androgen pathways that promote CRPC's progression. They significantly prolong survival and delay disease progression in patients resistant to standard hormone therapies, confirming their status as the top treatment for CRPC. The immunotherapy segment is expected to grow significantly from 2025 to 2034 due to the increasing awareness of its ability to provide lasting responses and improve survival for CRPC patients. Immunotherapy, including drugs like pembrolizumab, helps the immune system target cancer cells. While its effectiveness in prostate cancer varies, research and clinical trials are looking into combining it with other treatments to boost its results. Increased investment and positive study outcomes are likely to lead to advancements in this segment.
Regional Insights: North America held the largest revenue share of the global castrate-resistant prostate cancer market in 2024 due to a high prevalence of the disease, strong healthcare infrastructure, and significant investment in research and treatment. Leading pharmaceutical companies and ongoing clinical trials for advanced therapies support market growth. Increased awareness of prostate cancer and the importance of early detection and treatment also contribute. Government initiatives and funding help develop and adopt innovative treatments for CRPC.
Market Competitive Landscape:
Astellas Pharma, Inc, Pfizer, Inc, Sanofi, and Johnson & Johnson Services, Inc. are a few of the major players in the castrate-resistant prostate cancer market. Johnson & Johnson Services, Inc. contributes to the CRPC market with its drug Erleada (apalutamide), which improves overall survival compared to other treatments. Sanofi plays a vital role with its drug Jevtana (cabazitaxel), also improving overall survival rates in metastatic CRPC.
Recent Developments:
- In June 2024, AstraZeneca acquired Fusion Pharmaceuticals. This move strengthens AstraZeneca's cancer treatment options, especially in radio conjugates. Fusion's main program, FPI-2265, targets metastatic castration-resistant prostate cancer.
- In March 2024, Johnson & Johnson completed the acquisition of Ambrx Biopharma. Ambrx's synthetic biology platform helps develop advanced antibody-drug conjugates (ADCs), strengthening J&J's oncology pipeline, especially with ARX517 for metastatic castration-resistant prostate cancer.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Therapy. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Sanofi, Johnson & Johnson Services, Inc, Pfizer, Inc, Astellas Pharma, Inc, Bayer AG. |
Key Topics Covered in the Report:
- Global Castrate-resistant Prostate Cancer Market Size (FY’2021-FY’2034)
- Overview of Global Castrate-resistant Prostate Cancer Market
- Segmentation of Global Castrate-resistant Prostate Cancer Market By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy)
- Statistical Snap of Global Castrate-resistant Prostate Cancer Market
- Expansion Analysis of Global Castrate-resistant Prostate Cancer Market
- Problems and Obstacles in Global Castrate-resistant Prostate Cancer Market
- Competitive Landscape in the Global Castrate-resistant Prostate Cancer Market
- Details on Current Investment in Global Castrate-resistant Prostate Cancer Market
- Competitive Analysis of Global Castrate-resistant Prostate Cancer Market
- Prominent Players in the Global Castrate-resistant Prostate Cancer Market
- SWOT Analysis of Global Castrate-resistant Prostate Cancer Market
- Globa Castrate-resistant Prostate Cancer Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Castrate-resistant Prostate Cancer Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Castrate-resistant Prostate Cancer Market
7. Global Castrate-resistant Prostate Cancer Market, By Therapy (USD Million) 2021-2034
7.1. Chemotherapy7.2. Hormonal Therapy7.3. Immunotherapy7.4. Radiotherapy
8. Global Castrate-resistant Prostate Cancer Market, (USD Million) 2021-2034
8.1. Global Castrate-resistant Prostate Cancer Market Size and Market Share
9. Global Castrate-resistant Prostate Cancer Market, By Region, (USD Million) 2021-2034
9.1. Asia-Pacific
9.1.1. Australia9.1.2. China9.1.3. India9.1.4. Japan9.1.5. South Korea9.1.6. Rest of Asia-Pacific
9.2. Europe
9.2.1. France9.2.2. Germany9.2.3. Italy9.2.4. Spain9.2.5. United Kingdom9.2.6. Rest of Europe
9.3. Middle East and Africa
9.3.1. Kingdom of Saudi Arabia9.3.2. United Arab Emirates9.3.3. Qatar9.3.4. South Africa9.3.5. Egypt9.3.6. Morocco9.3.7. Nigeria9.3.8. Rest of Middle-East and Africa
9.4. North America
9.4.1. Canada9.4.2. Mexico9.4.3. United States
9.5. Latin America
9.5.1. Argentina9.5.2. Brazil9.5.3. Rest of Latin America
10. Company Profile
10.1. Sanofi
10.1.1. Company details10.1.2. Financial outlook10.1.3. Product summary10.1.4. Recent developments
10.2. Johnson & Johnson Services, Inc
10.2.1. Company details10.2.2. Financial outlook10.2.3. Product summary10.2.4. Recent developments
10.3. Pfizer, Inc
10.3.1. Company details10.3.2. Financial outlook10.3.3. Product summary10.3.4. Recent developments
10.4. Astellas Pharma, Inc
10.4.1. Company details10.4.2. Financial outlook10.4.3. Product summary10.4.4. Recent developments
10.5. Bayer AG
10.5.1. Company details10.5.2. Financial outlook10.5.3. Product summary10.5.4. Recent developments
10.6. Others
11. Conclusion
12. List of Abbreviations
13. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Castrate-resistant Prostate Cancer Market is projected to reach USD 30.78 billion by 2034, growing at a CAGR of 8.91% during the forecast period.
Castrate-resistant Prostate Cancer Market grew in Market size from 2025. The Market is expected to reach USD 30.78 billion by 2034, at a CAGR of 8.91% during the forecast period.
Castrate-resistant Prostate Cancer Market CAGR of 8.91% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Castrate-resistant Prostate Cancer Market size is USD 30.78 billion from 2025 to 2034.
Castrate-resistant Prostate Cancer Market is covered By Therapy.
The North America is anticipated to have the highest Market share in the Castrate-resistant Prostate Cancer Market.
The key players in the Market include Companies Covered Sanofi, Johnson & Johnson Services, Inc, Pfizer, Inc, Astellas Pharma, Inc, Bayer AG. and others.
This expansion is being driven by the rising prevalence of prostate cancer, particularly among the elderly, which is contributing to an increase in castrate-resistant prostate cancer (CRPC). Furthermore, advances in therapeutic alternatives, such as next-generation hormonal therapies, chemotherapy, and immunotherapies, are boosting market growth.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
